Acute Myeloid Leukemia: Molecular Mechanisms and Novel Therapies
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 20 December 2025 | Viewed by 10
Special Issue Editor
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous hematologic malignancy characterized by uncontrolled proliferation of myeloblasts and impaired hematopoietic differentiation. In recent years, advances in genomics, epigenetics, single-cell analysis, and multi-omics integration have substantially deepened our understanding of the molecular mechanisms underlying AML initiation, progression, and therapeutic resistance. At the same time, the emergence of novel therapeutic strategies, including targeted inhibitors, epigenetic modulators, and immunotherapies, is rapidly reshaping the clinical landscape and offering new hope for patients.
This Special Issue of Cells aims to highlight cutting-edge basic, translational, and clinical research that elucidates the complex pathobiology of AML and drives the development of next-generation therapeutic approaches. We welcome original research articles, reviews, and perspectives that explore key areas such as genetic and epigenetic alterations, leukemia stem cells, metabolic reprogramming, clonal evolution, tumor microenvironment dynamics, and mechanisms of therapeutic resistance and response. By bringing together diverse insights and interdisciplinary approaches, this Issue seeks to accelerate progress toward more effective, precise and durable treatments for AML patients.
Dr. Xiangguo Shi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia (AML)
- genomics and epigenetics
- therapeutic resistance
- metabolic reprogramming
- clonal evolution
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
